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94Objective: The objective of the present study was to assess the safety and feasibility of computed tomography
lymphography by transbronchial injection of a water-soluble extracellular computed tomography contrast agent.
Methods: From April 2010 to May 2011, patients with clinical stage I non–small cell lung cancer who were
candidates for lobectomy were enrolled in the present study. An ultrathin bronchoscopewas inserted to the target
bronchus under the guidance of virtual bronchoscopic navigation images. Computed tomography images of the
chest were obtained 0.5 and 5 minutes after 2 or 3 mL of iopamidol was injected through a microcatheter.
Sentinel nodes were identified when the maximum computed tomography attenuation value of the lymph nodes
on the postcontrast computed tomography images increased by 30 Hounsfield units or more compared with the
precontrast images. Patients underwent lobectomy with standard lymph node dissection.
Results: The ultrathin bronchoscope could access the targeted bronchus, and iopamidol was delivered into the
peritumoral area in all 13 patients without any complications. Sentinel nodes were identified in 12 (92.3%) of
the 13 patients. The average number of sentinel nodes was 1.5 (range, 1–2). Pathologic examination revealed
metastatic lymph nodes in 2 patients. Metastatic nodes were included with the sentinel nodes.
Conclusions: Computed tomography lymphography by transbronchial injection of iopamidol was a safe and
feasible method to identify the sentinel nodes in patients with clinical stage I non–small cell lung cancer.
(J Thorac Cardiovasc Surg 2012;144:94-9)A sentinel node (SN) is defined as the first node draining
a tumor and should be the first site affected by lymphatic
dissemination. SN navigation surgery has been developed
to reduce the extent of lymphadenectomy,with a consequent
reduction in operative mortality and complications, espe-
cially in breast cancer and malignant melanoma surgery.1,2
However, SN navigation surgery has not been popular for
patients with non–small cell lung cancer (NSCLC),
because it is not considered necessary. The American
College of Surgeons Oncology Group Z0030 study group
concluded in their large, prospective, multi-institutional,
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The Journal of Thoracic and Cardiovascular Surgedid not increase operative mortality or the number or type
of complications compared with lymph node sampling in
patients with early-stage NSCLC.3
However, the background of patients with NSCLC has
been changing. Recently, with the increased incidence of
small-size NSCLC, segmentectomy is again under evalua-
tion for clinical stage T1aN0 NSCLC.4 Several reports
have demonstrated that survival and local recurrence were
similar between patients treated with segmentectomy and
those treated with lobectomy.5-8 The most important issue
regarding this comparison is whether postoperative local
recurrence is increased by segmentectomy. In the ongoing
trial and previous reports regarding segmentectomy,
the eligibility criteria for segmentectomy included
a prerequisite of no lymph node metastasis by
intraoperative findings because node-positive cases have
a chance to be locoregionally controlled and to be correctly
staged by converting to lobectomy.4-8 Patients with clinical
stage IA NSCLC had an incidence of pathologic stage N1
and N2 of 4.8% to 7.6% and 9.5% to 13.3%,
respectively.9,10 Also, skip metastasis to the mediastinal
lymph nodes has been reported in 18% to 30% of
patients with NSCLC.11-13 Therefore, intraoperative
sampling and frozen section analysis of the true SNs is
important in ensuring the radicality of segmentectomy.
We have developed a novel method of computed tomog-
raphy lymphography (CTLG) with transbronchial injectionry c July 2012
Abbreviations and Acronyms
CTLG ¼ computed tomography lymphography
MDCT ¼ multidetector computed tomography
NSCLC ¼ non–small cell lung cancer
SN ¼ sentinel node
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midol. This method aims to identify the SNs in patients
with preoperative NSCLC. The present report shows
a new technique of CTLG by transbronchial injection of io-
pamidol, and the purpose of the present study was to eval-
uate the safety and feasibility of this method.METHODS
Eligibility
From April 2010 to May 2011, patients with clinical stage I NSCLC,
who were candidates for lobectomy with standard hilar and mediastinal
lymph node dissection, were enrolled in the present study. Patients were ex-
cluded if they had an allergy to iodinated contrast medium or a history of
asthma. The ethics committee of Tokushima University Hospital approved
the study protocol for CTLG with transbronchial injection of iopamidol in
March 2010. All patients provided informed consent.
Objective
The objective of the study was to assess the safety and feasibility of
newly developed CTLG with transbronchial injection of iopamidol.
CTLG Technique With Transbronchial Injection of
Iopamidol
Virtual bronchoscopic navigation images were rendered using Bf-NAVI
(Olympus, Tokyo, Japan) using 1-mm-thickness multidetector CT
(MDCT) scan data before CTLG. Before lymphography, CT was per-
formed using a MDCT scanner (Somatom Sensation 16; Siemens, Erlan-
gen, Germany) with the following parameters: 120 kV, 0.75 mm
collimation, 16 detectors, pitch 0.95, and rotation time 0.5 second. All
lung fields were scanned during single breath-hold inhalations. Patients
received mild sedation with 1 to 2 mg of midazolam. Local anesthesia of
the upper respiratory tract was induced with 4% lidocaine. After a brief ob-
servation of the tracheobronchial lumen using a conventional broncho-
scope (BF type 260; Olympus; external diameter, 4.9 mm), an ultrathin
bronchoscope (BF type XP260F; Olympus: external diameter, 2.8 mm)
was advanced as far as possible to the target bronchus by comparing the di-
rect vision and navigation images. A microcatheter (FasTracker-325,
Boston Scientific, Tokyo, Japan) was inserted through a channel in the ul-
trathin bronchoscope, and the tip of the catheter was adjusted using C-arm
fluoroscopy guidance. After the ultrathin bronchoscope was detached from
the light source and video processor while the tip of the catheter and bron-
choscope remained inserted in the target bronchus, the patient table was
slid into the CT scanner. A 5-mL syringe was attached to the microcatheter
and 2 or 3 mL of iopamidol (Iopamiron-300; Bayer HealthCare, Osaka,
Japan) was injected transbronchially into the peritumoral area.
Iopamiron-300 has a molecular weight of 777.09 Daltons, the solute has
an iodine concentration of 300 mg/mL, the viscosity is 4.4 mPa/s, and
the osmolarity is less than 3 times the osmolarity of physiologic saline. Af-
ter the microcatheter and ultrathin bronchoscope were removed from the
patient, MDCT images (1-mm thickness) of the chest were obtained 0.5
and 5 minutes after injection, according to our preliminary data comparing
3 cases (data not shown).The Journal of Thoracic and CSN Identification
Respective CTLG and contrast-enhanced CT images were checked si-
multaneously onaworkstation (AquariusNetStation, version4;TeraRecon,
San Mateo, Calif). The maximum CTattenuation value of all lymph nodes,
including the pulmonary, hilar, andmediastinal lymph nodes, was measured
by circling the lymph nodes in the region of interest. A lymph node was de-
fined as the SNwhen themaximumCT value of the lymph node on the post-
contrast CT images (0.5 minutes after injection) increased by 30 Hounsfield
units (HU) or more compared with that on the precontrast images. Themax-
imumCTvalues are presented as themean standard deviation. Nodal clas-
sification was determined according to the Unio Internationalis Contra
Cancrum staging system, version 7.14A 3-dimensionalCTimagewas recon-
structed on the same workstation using 1-mm-thickness MDCT images.
Surgery and Pathologic Examination
Patients underwent video-assisted thoracic surgery lobectomy with
standard hilar and mediastinal lymph node dissection (2 or 3 ports and
4–8-cm access incision without rib spreading devices). SNs were harvested
according to the CTLG findings, including the 2- and 3-dimensional im-
ages. The SNs in the intrapulmonary stations were harvested on the back
table, and the SNs in the hilar and mediastinal stations were harvested be-
fore lobectomy. All lymph nodes, including the SNs, were histopathologi-
cally examined using standard hematoxylin and eosin staining. The TNM
classification was determined according to the Unio Internationalis Contra
Cancrum staging system, version 7.RESULTS
Fourteen patients with clinical stage I NSCLC (or sus-
pected of having NSCLC) were enrolled in the present
study. One patient was excluded because the intraoperative
frozen section analysis revealed that the lesion had inflam-
matory changes. The 13 patients included 4 men and 9
women, with a mean age of 65.7 years (range, 47–76 years).
The mean tumor size was 2.1 mm (range, 1.4–3.4 mm).
The histologic type was adenocarcinoma in 11 patients
and squamous cell carcinoma in 2. The tumor location
was the right upper lobe in 7, right lower lobe in 2, left upper
lobe in 3, and left lower lobe in 1. The pathologic TNM
stage was T1aN0M0 in 5, T1bN0M0 in 2, T2aN0M0 in 4,
T1bN1M0 in 1, and T1aN2M0 in 1 (Table 1). The tumor
locations and target bronchi are listed in Table 2. The virtual
bronchoscopic images displayed the routes to a median of
the fifth bronchus (third to sixth).
CTLG was usually performed after CT-guided transbron-
chial tumor biopsy (10/13) or aCT-guidedmetallic coilmark-
ing (1/13) and was accomplished within 10 minutes. The
ultrathin bronchoscope accessed the targeted bronchus, and
iopamidol was delivered into the peritumoral area in all pa-
tients without any complications (Figure 1). In several cases,
oval-shaped lymph nodes were clearly enhanced on the post-
lymphography CT images (Figure 2, C). Three-dimensional
CT images rendered by 1-mm thickness MDCT images 0.5
minute after CT lymphography clarified the position of
a SN and the structure of the hilum (Figure 2, D). Lymphatic
vesselswerevisualized as streamlines in2patients (Figure3).
SNs were identified in 12 (92.3%) of the 13 patients, and
the average number of SNs was 1.5 (range, 1–2). SNs wereardiovascular Surgery c Volume 144, Number 1 95
TABLE 1. Patient characteristics
Characteristic Value
Age (y) 65.7  7.6
Gender
Male 4
Female 9
Tumor size (cm) 2.1  0.6
Tumor location
RUL 7
RLL 2
LUL 3
LLL 1
Histologic type
Adenocarcinoma 11
Squamous cell carcinoma 2
Pathologic TNM stage
T1aN0M0 5
T1bN0M0 2
T2aN0M0 4
T1bN1M0 1
T1aN2M0 1
Data presented as mean  standard deviation or numbers. RUL, Right upper lobe;
RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
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the mediastinal station in 4 patients. The maximum CT
value of the SNs on the precontrast and postcontrast images
0.5 and 5 minutes after injection was 111  32 HU, 269 
243 HU, and 204 184 HU, respectively. Of the 12 patients
in whom SNs were detected, 10 had no metastasis in the
SNs and no metastasis in the other lymph nodes. In patient
4, CTLG identified SNs in stations 5 and 13, and pathologic
examination revealed a solo skip metastasis to the medias-
tinum in station 5. In patient 11, CTLG identified SNs in sta-
tions 2 and 10, and a pathologic examination revealed
metastatic lymph nodes in stations 10 and 11.TABLE 2. Tumor location and sentinel lymph node station
Pt. no.
Age
(y) Gender
Tumor
size (cm)
Histologic
type
Tumor
location
Targeted
bronchus
1 64 F 2.3 ACA Right S3 Right B3aiax
2 64 F 1.6 ACA Right S3b Right B3biia
3 70 F 2.2 ACA Right S3 Right B3ai
4 61 M 1.5 ACA Left S1þ2 Left B1þ2aiib
5 76 F 3.2 ACA Left S9 Left B9biibx
6 47 F 2.0 ACA Right S9 Right B9biib
7 65 F 1.6 ACA Right S9a Right B9ai
8 68 F 1.4 ACA Right S2b Right B2bia
9 66 M 2.2 SCC Right S2 Right B2aiia
10 59 M 1.8 ACA Left S1þ2a Left B1þ2ai
11 76 F 2.4 ACA Right S1 Right B1b
12 67 F 2.0 ACA Right S2 Right B2biia
13 71 M 3.4 SCC Left B4 Left B4bii
The branch of the bronchus, which extends to superior, dorsal, or lateral side, was defined as
was defined as ii, b, or y. Pt. no., Patient number; SN, sentinel lymph node; LN, lymph node
carcinoma.
96 The Journal of Thoracic and Cardiovascular SurgeDISCUSSION
Limited numbers of studies have reported SN identifica-
tion for patients with NSCLC. SN biopsy using isosulfan
blue dye showed an unsatisfactorily low detection rate
caused by anthracotic black lymph nodes.15 The Cancer
and Leukemia Group B 140203 trial failed to show a satis-
factory SN identification rate using a radiolabeled tracer
because of the aerosolization of radioactivity and shine-
through effect, making it difficult to evaluate the pulmonary
and hilar lymph nodes.16 In contrast, Nomori and col-
leagues17 reported a SN identification rate of 83% in the
SN navigation segmentectomy trial adopting the ex vivo
SN identification method. However, their method requires
surgeons to perform segmentectomy before SN identifica-
tion and when intraoperative frozen section analysis of
the SNs showed metastasis, conversion to lobectomy must
be done. The radiolabeled tracer method has the disadvan-
tage of exposing both patients and surgeons to radiation. Ya-
mashita and colleagues18 reported an SN identification rate
of 80.7% using a video-assisted thoracoscopic indocyanine
green fluorescence imaging system. Because infrared light
cannot reach lymph nodes located deeply in the lung paren-
chyma or mediastinal fat tissue, ex vivo SN identification is
needed to achieve as accurate an evaluation as that produced
using the radiolabeled tracer method. In 2004, Suga and col-
leagues19 reported a method of SN identification using
a CT-guided percutaneous injection of iopamidol into peri-
tumoral lung tissue. They successfully identified SNs in all
9 patients with preoperative NSCLC without any complica-
tions. However, in 2006, the same group reported that cere-
bral air embolisms occurred using this method.20
Air embolism is a rare, but potentially lethal, complication
encountered during percutaneous transthoracic needle bi-
opsy or marking.21,22 The percutaneous transthoracic
approach also has other potential risks, includingIopamidol
volume (mL)
SN
station
SNs
(n)
Metastatic
station
Resected
LN (n)
Pathologic
stage
2 4R, 12 2 — 22 IA
x 2 11 1 — 18 IA
2 11 1 — 16 IA
y 2 5, 13 2 5 13 IIIA
2 7, 12 2 — 23 IB
y 2 13 1 — 7 IA
2 11 1 — 13 IA
3 12 2 — 10 IB
3 11, 12 2 — 27 IB
3 13 1 — 10 IA
3 2R, 10 2 10, 11 12 IIA
3 — — — 6 IA
3 10, 13 2 — 25 IB
i, a, or x; the branch of the bronchus, which extends to inferior ventral or medial side,
; F, female; ACA, adenocarcinoma; S, segment of lung;M,male; SCC, squamous cell
ry c July 2012
FIGURE 1. Fluoroscopy finding during lymphography showing iopami-
dol injected into the peripheral bronchioalveolar area near the tumor
through the ultrathin bronchoscope.
Takizawa et al General Thoracic Surgery
G
T
Spneumothorax, bleeding, and pleural tumor seeding. High-
risk examinations are not acceptable for patients with early-
stage NSCLC.FIGURE 2. Computed tomography (CT) lymphography in patient 7 in Table 2. A
CT (CTLG) image. B, Iopamidol is delivered into the peritumoral lung tissue of r
CTLG image (arrow). D, Three-dimensional CT image rendered by 1-mm-thickn
a sentinel lymph node and the structure of the hilum. Arrows, a sentinel node; ar
The Journal of Thoracic and CTheoretically, our method has the following advantages
compared with previous methods. First, the transbronchial
approach is free of the risk of pneumothorax, bleeding,
and pleural tumor seeding compared with the percutaneous
transthoracic approach. Second, CTLG does not expose sur-
geons to radiation. Third, CTLG can detect lymph nodes lo-
cated deeply in the lung parenchyma or mediastinal fat
tissue. Also, the surgeons can understand the location of
the identified SNs preoperatively by interpreting the post-
CTLG images, which demonstrate the position of the SNs
and the structure of the hilum or mediastinum. Finally, be-
cause it is not necessary to dissect all lymph nodes to iden-
tify SNs, surgeons only have to sample the SNs identified
preoperatively using CTLG and submit them for intraoper-
ative pathologic diagnosis. However, if the SNs show
metastasis, the segmentectomy should be converted to
lobectomy.
CTLG by transbronchial injection of iopamidol was
safely performed in 14 patients with preoperative NSCLC
without any complications. Virtual bronchoscopic images
displayed routes to a median of the fifth bronchus (third
to sixth), the ultrathin bronchoscope could access the tar-
geted bronchus, and iopamidol was delivered into the peri-
tumoral area in all 13 patients. The method was usually
combined with CT-guided transbronchial lung biopsy or
metallic coil marking, and it took about 10 minutes to, A tumor diameter of 1.6 cm is seen in right station 9a on a prelymphography
ight station 9. C, An oval-shaped lymph node is clearly enhanced on a post-
ess multidetector CT images 0.5 minute after CTLG clarifies the position of
rowhead, iopamidol injected into the peritumoral lung tissue.
ardiovascular Surgery c Volume 144, Number 1 97
FIGURE 3. Three-dimensional computed tomography (CT) image ren-
dered by 1-mm-thickness multidetector CT images 0.5 minute after CT
lymphography showing a lymphatic vessel (patient 5 in Table 2). Arrows,
A lymphatic vessel; arrowheads, iopamidol injected into peritumoral lung
tissue.
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rate of our CTLG method was 92.3%, which was better
than that using previous methods.15-19 Pathologic
examination revealed metastatic lymph nodes in 2
patients. The metastatic nodes were included in the SNs.
We could not identify any SNs in 1 patient (patient 12), in
whom several mediastinal lymph nodes had small
calcifications. Although the reason no lymph nodes were
enhanced in this case is unclear, there might be difficulty
in identifying SNs in patients with a history of tuberculosis.
The present study had some limitations and issues when
CTLG is adopted for SN navigation segmentectomy. First,
2 patients with pathologically confirmed metastases to the
lymph nodes were insufficient to assess the accuracy of
CTLG. Second, the potential of CTLG in identifying intra-
pulmonary SNs before segmentectomy needs to be evalu-
ated in another study, because SNs in stations 12 and 13
were harvested on the back table in the present study and
SNs in the hilar and mediastinal stations were harvested be-
fore lobectomy. Finally, the development of high-accuracy
intraoperative pathologic or genetic evaluations combined
with CTLG for SN identification is required in future
studies.
Previous reports regarding CTLG for patients with breast
cancer showed that lymphatic vessels could be visualized
clearly as stream lines from the injection site to the axillary
SNs.23 In the present study, lymphatic vessels were visual-
ized as stream lines in only 2 patients. In most cases,98 The Journal of Thoracic and Cardiovascular Surgebronchi that reached a segment including tumor were dif-
fusely enhanced on the post-CTLG images. These findings
indicate that the lymphatic networks of the lung densely
surround the bronchi and that these networks are responsi-
ble for the diversity of lymphatic spread in patients with
NSCLC. Suga and colleagues19 also reported that bronchi
were diffusely enhanced on their CTLG images using the
percutaneous transthoracic injection of iopamidol.
In the present study, the maximum CT value of the SNs at
0.5 minute was greater than at 5 minutes after injection of
the contrast agent. We set the timing of the CT scan accord-
ing to our preliminary data comparing 3 cases: 0.5 versus
5, 1 versus 10, and 2 versus 15 minutes after injection
(data not shown). The former times showed better visualiza-
tion of the enhanced SNs than the latter times in each com-
parison, and the pairing of 0.5 and 5 minutes showed the
best visualization. Suga and colleagues19 performed CT
scans every minute for 5 minutes after percutaneous trans-
thoracic injection of iopamidol. They showed that the max-
imum CT value of the SN had reached its peak at 1 minute
and then tapered, indicating that increased interstitial pres-
sure when a contrast agent is injected is one of the most im-
portant factors influencing the volume of contrast agent that
penetrates into the lymphatic systems during CTLG.CONCLUSIONS
CTLG by transbronchial injection of iopamidol was
a safe and useful method to identify SNs in preoperative pa-
tients with NSCLC. The post-CTLG images clarified the
position of the SNs and the structure of the hilum, which
could help surgeons to acquire an intuitive image during
SN navigation segmentectomy. Although these results are
preliminary, this method has the potential to improve the ac-
curacy of SN biopsy during segmentectomy in patients with
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